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ABSTRACT
Chronic spontaneous urticaria (CSU) is a condition characterised by the presence of hives with/without angioedema that affects 
individuals on more days than not for 6 weeks or more. This can be a very debilitating condition affecting the quality of life. Here, we 
report 3 cases of severe prolonged chronic spontaneous urticaria in 7-year-old, 20-year-old and 25-year-old individuals that went into 
rapid remission following the treatment with Omalizumab, anti-IgE monoclonal antibody.
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Urticaria is a dermatological disorder that manifests as raised erythematous lesions that range in size. They are pruritic and typically resolve with no changes to the appearance 
of the skin. Urticarial lesions may be associated with episodes of 
‘angioedema’ [1].Usually, second-generation antihistamines are 
the first line of treatment in chronic urticaria [2]. Many a time, 
pharmacotherapy with antihistamines alone may not be of help. In 
the majority of the situations, patients continue these medications for 
a long period of time, with/without desired effect and sometimes, the 
treating clinician will have to resort to the use of immunosuppressant 
like Cyclosporine. The treatment may be unresponsive to traditional 
and increasing doses of anti-histamines. In such cases, Omalizumab, 
an anti-IgE monoclonal antibody is the treatment option [3] . We 
report 3cases of severe chronic spontaneous urticaria that rapidly 
resolved following treatment with Omalizumab.
CASE SERIES
1st Case: A 7-year-old female patient was referred to the Allergy 
and Immunology clinic by her Paediatrician. She presented 
with a two-month history of urticaria with intermittent episodes 
of angioedema. Her initial symptoms included facial pruritis, 
periorbital erythema and angioedema involving the upper and 
lower lips. Within 30 minutes of her first episode of angioedema, 
she developed widespread urticaria which responded to treatment 
with antihistamines. The following day, she experienced a 
recurrence of the symptoms and continued to have almost daily 
symptoms of urticaria with intermittent episodes of angioedema. 
These episodes led to her being bullied in school and led to school 
absenteeism many a time. 
She was commenced on alternative anti-histamine by her 
Paediatrician but continued to develop urticaria and experience 
swellings of the hands and feet. Her treatment was escalated at 
her initial visit to Allergy and Immunology Clinic to fexofenadine 
180mg twice a day with an additional 10–20mg of cetirizine. In 
addition, montelukast, a leukotriene receptor antagonist, was 
commenced. The number of hives and degree of pruritis were 
graded using an objective scoring system known as the Urticaria 
Activity Score 7 (UAS7) that provides a weekly average score 
out of a maximum score of 40. The patient recorded weekly 
UAS7 scores of 32, despite treatment with maximum doses of 
antihistamines and montelukast. Therefore, Anti-IgE therapy with 
the monoclonal antibody, Omalizumab, was offered. The parents 
consented for the same and she was started on 300 micrograms of 
subcutaneous Omalizumab once in 4 weeks.
About 4 weeks after this intervention, her UAS7 score fell to 
10 and then to 2-4 after the second dose and she has remained 
in remission (UAS 7 score 0) for 11 months after about 4 doses 
of Omalizumab. Initial investigations including full blood count, 
renal function, liver function and thyroid function tests were all 
within the normal ranges. She was happy with her remission and 
it helped her in her academic activities as well. 
2ndCase: A 20-year-old male patient was referred to the 
Allergy and Immunology Clinic by his Ophthalmologist in view 




Cholinergic urticarial Rise in body temperature
Cold urticarial Upon contact with cold objects
Vibration urticaria
Contact with a vibrating 
stimulus
Pressure urticaria
May be associated with 
delayed onset of wheals on 
application of pressure
Aquagenic urticaria Contact with water
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of persisting allergic rhinoconjunctivitis of 1-year in spite of 
optimal local treatment with eye formulations. Incidentally, he 
also had a history of urticaria of 6-month duration along with 
the presenting complaints. He was being treated with an oral 
antihistamine for his urticaria by his general practitioner (GP), 
with recurrence of his symptoms. He was escalated to oral 
fexofenadine 180mg twice daily and montelukast 10mg, once 
daily at his initial visit to Allergy and Immunology clinic. UAS7 
was used to grade the number of hives and degree of pruritis 
as was done in the earlier patient. The patient recorded weekly 
UAS7 score of 30, in spite of higher doses of antihistamines. 
Hence, the decision to start therapy with Omalizumab was 
mutually taken after due discussion with the patient and his 
family. He was started on 300 micrograms of subcutaneous 
Omalizumab once in 4 weeks.
After about 6-8 weeks into this therapy, his UAS7 score 
decreased to about 10 and then to 0 after the third dose and 
has remained in remission for a year, after a total of 6 doses of 
Omalizumab. His allergic rhinoconjunctivitis symptoms have 
also improved concurrently.
3rd Case: A 25-year-old male patient was referred to the 
Allergy and Immunology Clinic by his dermatologist with a 
history of chronic urticaria since last few months. He was treated 
with oral antihistamines, with increased dose, for a few weeks, 
with relapse of symptoms. In view of the severity of symptoms, 
the decision of starting Omalizumab was taken after discussion 
with the patient. Inspite of 3-4 doses of 300mcg subcutaneous 
Omalizumab, the patient had minimal relief. Hence, we re-visited 
the history with the patient. Upon review, the patient mentioned 
that he had pigeons at his home. On advice to avoid the same, the 
patient got better within a few weeks. This is to emphasise that 
medical history and examination is of utmost importance, to be 
considered at each step of the treatment if there are no desired 
results with appropriate medical management.  
DISCUSSION
Urticaria is a heterogeneous, common group of disorders 
characterised by the appearance of fleeting wheals, lasting for 
1-24 hours and/or angioedema lasting for up to 72 hours. The 
prevalence in children is estimated to be around 3-8% with 
chronic urticaria being less common. Acute urticaria typically 
lasts less than 24 hours and is usually self-limiting. It is mainly 
seen in association with infections in children. Acute urticaria 
can also occur in combination with other systemic symptoms as 
part of an allergic reaction upon exposure to certain foods(milk, 
eggs, nuts, peanut), drugs like penicillins, stinging insect 
venom (wasp, honey bee) or skin contact with an allergen. 
Symptoms can be treated with non-sedating anti-histamines if 
very bothersome. 
Chronic spontaneous urticaria (CSU) is defined as daily or 
almost daily urticaria for at least 6 weeks [1]. In up to 50% of 
patients, urticaria may be associated with episodes of angioedema 
[2]. Chronic urticaria (CU) is rarely caused by allergies and is 
not a life-threatening condition. These features are the result of 
degranulation of mast cells with the release of granule contents, 
predominantly histamine.
Resolution of symptoms occurs in approximately 80% patients 
within 1 year of onset of symptoms but can persist beyond five 
years in about 10 % of patients [4,5]. It often lasts less than 5-10 
years. Quality of life is often severely affected [6, 7]. In Inducible 
forms of Chronic Urticaria, avoidance of the trigger is preferred, 
though it may not be feasible all the time.
Patients often present to their GP and are referred for further 
assessment and management by Immunologists, Allergists or 
Dermatologists when first-line treatment with antihistamines fail 
to control the symptoms. The mainstay of treatment is high dose 
antihistamines and leukotriene receptor antagonists [1]. In recent 
years, the anti-IgE monoclonal antibody therapy, Omalizumab, 
has been used as an effective treatment for patients who fail to 
respond to first-line therapy.The algorithm for the treatment of 
chronic urticaria [8] is given in Fig. 1.
As highlighted in our case series, patients with recalcitrant 
chronic urticaria to antihistamine went into remission soon after 
initiation of therapy with Omalizumab. They are continued to 
follow up periodically, to assess the quality of life and relapse 
of urticaria. Only a single patient, had mild relapse of symptoms 
about 10 months of cessation of therapy with Omalizumab, which 
was treated with second-generation antihistamines for three days 
and has been better since.
Figure 1: Algorithm for treatment of chronic urticaria.
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CONCLUSION
There is definitely a need for more clinical data from our country 
in the setting of treatment of Chronic Urticaria to streamline the 
use of biologicals like Omalizumab.Clinicians should recognise 
the potential role of Omalizumab in treating such chronic urticaria 
cases. There should be a low threshold to consider this option for 
treatment in cases of resistance to treatment with anti-histamines.
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